- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
SANOFI-AVENTIS / MERIAL
M.5614
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
On 11 August 2009, the Commission received a notification pursuant to Article 4 of Council Regulation
(EC) No 139/2007 of a proposed concentration by which Sanofi-Aventis’ control over Merial will
change from joint control to sole control within the meaning of Article 3(1)(b) of the Council Regulation.
The business activities of the undertakings are:
−
For Sanofi-Aventis: research, development, manufacture and marketing of human
healthcare products, including vaccines, both throughout the EU and worldwide.
−
For Merial: research, development, manufacture and marketing of animal health
products, including vaccines both throughout the EU and worldwide.
As the Transaction will consist of the transition from joint control to sole control, and since there are no
horizontal overlap and negligible vertical overlaps, Sanofi-Aventis considers that the Transaction
should properly be notified via Short Form CO.